G
George R. Pettit
Researcher at Arizona State University
Publications - 850
Citations - 32782
George R. Pettit is an academic researcher from Arizona State University. The author has contributed to research in topics: Bryostatin 1 & Combretastatin. The author has an hindex of 89, co-authored 848 publications receiving 31759 citations. Previous affiliations of George R. Pettit include Kanagawa University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
TL;DR: The African treeCombretum caffrum (Combretaceae) has been found to contain a powerful inhibitor of tubulin polymerization (IC502–3 μM), the growth of murine lymphocytic leukemia and human colon cancer cell lines.
Journal Article
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
TL;DR: Vascular shutdown, within experimental and human breast cancer models in vivo following systemic drug administration, was demonstrated with a reduction in functional vascular volume of 93% at 6 h following drug administration and persisted over the next 12 h, with corresponding histology consistent with hemorrhagic necrosis resulting from vascular damage.
Journal ArticleDOI
Isolation and Structure of Bryostatin 1
George R. Pettit,Cherry L. Herald,Dennis L. Doubek,Delbert L. Herald,Edward Arnold,Jon Clardy +5 more
Journal ArticleDOI
The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10
George R. Pettit,Yoshiaki Kamano,Cherry L. Herald,Albert A. Tuinman,Fred E. Boettner,Haruhisa Kizu,Jean M. Schmidt,L. Baczynskyj,L. Baczynskyj,Kenneth B. Tomer,Kenneth B. Tomer,Roger J. Bontems +11 more
Patent
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
George R. Pettit,Jozsef Barkoczy +1 more
TL;DR: In this paper, novel tetrapeptides bearing modified phenethyl amides are elucidated and synthesized and found to exhibit tumor inhibiting effects when measured against the NCI screen for six major types of human cancer and against the murine P388 lymphocytic cell line.